BACKGROUND: The limited therapeutic options and inconsistent treatment efficacy of Intestinal Behcet's disease complicate its management, with the absence of standardized guidelines further exacerbating the challenges faced by clinicians. CASE PRESENTATION: In this case report, we present a patient with refractory intestinal Behcet's disease who experienced treatment failure with prior biologic agents. This case sheds light on managing this complex scenario with Janus kinase (JAK) inhibitors, the patient achieved mucosal healing after switching to Upadacitinib. CONCLUSION: This case underscores the potential of Upadacitinib as an effective alternative for managing difficult cases of intestinal Behcet's disease.
No clinical trial protocols linked to this paper
Clinical trials are automatically linked when NCT numbers are found in the paper's title or abstract.PICO Elements
No PICO elements extracted yet. Click "Extract PICO" to analyze this paper.
Paper Details
MeSH Terms
Associated Data
No associated datasets or code repositories found for this paper.
Related Papers
Related paper suggestions will be available in future updates.